Issue 21, 2023

Recent advances in type I organic photosensitizers for efficient photodynamic therapy for overcoming tumor hypoxia

Abstract

Photodynamic therapy (PDT) with an oxygen-dependent character is a noninvasive therapeutic method for cancer treatment. However, its clinical therapeutic effect is greatly restricted by tumor hypoxia. What's more, both PDT-mediated oxygen consumption and microvascular damage aggravate tumor hypoxia, thus, further impeding therapeutic outcomes. Compared to type II PDT with high oxygen dependence and high oxygen consumption, type I PDT with less oxygen consumption exhibits great potential to overcome the vicious hypoxic plight in solid tumors. Type I photosensitizers (PSs) are significantly important for determining the therapeutic efficacy of PDT, which performs an electron transfer photochemical reaction with the surrounding oxygen/substrates to generate highly cytotoxic free radicals such as superoxide radicals (˙O2) as type I ROS. In particular, the primary precursor (˙O2) would progressively undergo a superoxide dismutase (SOD)-mediated disproportionation reaction and a Haber–Weiss/Fenton reaction, yielding higher cytotoxic species (˙OH) with better anticancer effects. As a result, developing high-performance type I PSs to treat hypoxic tumors has become more and more important and urgent. Herein, the latest progress of organic type I PSs (such as AIE-active cationic/neutral PSs, cationic/neutral PSs, polymer-based PSs and supramolecular self-assembled PSs) for monotherapy or synergistic therapeutic modalities is summarized. The molecular design principles and strategies (donor–acceptor system, anion–π+ incorporation, polymerization and cationization) are highlighted. Furthermore, the future challenges and prospects of type I PSs in hypoxia-overcoming PDT are proposed.

Graphical abstract: Recent advances in type I organic photosensitizers for efficient photodynamic therapy for overcoming tumor hypoxia

Article information

Article type
Review Article
Submitted
15 Marts 2023
Accepted
26 Apr. 2023
First published
28 Apr. 2023

J. Mater. Chem. B, 2023,11, 4600-4618

Recent advances in type I organic photosensitizers for efficient photodynamic therapy for overcoming tumor hypoxia

B. Lu, L. Wang, H. Tang and D. Cao, J. Mater. Chem. B, 2023, 11, 4600 DOI: 10.1039/D3TB00545C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements